Importantly, our study identifies a subset of early stage lung cancer patients with increased probability of recurrence based on “at risk” immune phenotype characterized by intra-tumoral composition of increased Treg and macrophage populations, as well as decreased non-Treg CD4+ T cells and plasma cells. This evidence concerns the gene CD4 and lung cancer.